Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1625 1626 1682
This examiner grants 69% of resolved cases
Quincy Andre McKoy is a patent examiner in Tech Center 1600, working within Art Unit 1625. The examiner has 112 resolved cases and an allowance rate of 68.8 percent. This 68.8 percent rate reflects the proportion of applications that reach a grant. For the 112 cases handled, this data provides a basis for understanding the probability of success during the examination process. The volume of resolved cases reflects the examiner's experience within Tech Center 1600.
The median days to allowance for this examiner is 1192. This 1192-day timeline represents the duration for an application to move from filing to a grant. Applicants should consider this period when planning their patent strategy and resource allocation. The volume of 112 resolved cases suggests that this duration is a consistent aspect of the examiner's workflow in Art Unit 1625. This median provides a specific metric for evaluating the expected length of prosecution.
The data shows an interview lift of 39.4 percent. This 39.4 percent lift represents the change in the likelihood of allowance when an interview is conducted. It suggests that direct communication is a method for addressing the probability of a grant. For practitioners, utilizing an interview is an option to navigate the prosecution process and achieve a positive outcome. Practitioners can use this lift to evaluate the potential benefits of direct engagement.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18710130 | BRM DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | Non-Final OA | Genentech, Inc. |
| 18684143 | ACID CERAMIDASE INHIBITORS AND USES THEREOF | Final Rejection | The Regents of the University of California |
| 18570398 | (1,4,5-TRISUBSTITUTED-1H-PYRAZOL-3-YL)OXY-2-ALKOXY ALKYL ACIDS AND THEIR DERIVATIVES, THEIR SALTS AND THEIR USE AS HERBICIDAL AGENTS | Non-Final OA | Bayer AKtiengesellschaft |
| 18612647 | BROMODOMAIN INHIBITORS FOR CANCER THERAPY | Non-Final OA | University of Tennessee Research Foundation |
| 18473802 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND METHODS OF USE | Non-Final OA | YALE UNIVERSITY |
| 18789815 | PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18525536 | METHYLQUINAZOLINONE DERIVATIVES | Non-Final OA | Hoffmann-La Roche Inc. |
| 18853736 | Cancer Treatments Using MTA-Cooperative PRMT5 Inhibitors | Non-Final OA | AMGEN INC. |
| 16627146 | CHEMOTHERAPY FOR CANCER USING AZABICYCLO COMPOUND | Final Rejection | TAIHO PHARMACEUTICAL CO., LTD. |
| 18964918 | PROCESS FOR PREPARING (5S)-{[2-(4-CARBOXYPHENYL)ETHYL] |2-(2-{|3-CHLORO-4'-(TRIFLUOROMETHYL)BIPHENYL-4- YL]METHOXY}PHENYL)ETHYL]AMINOL-5,6,7,8-TETRAHYDROQUINOLINE-2-CARBOXYLIC ACID AND ITS CRYSTALLINE FORMS FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | Non-Final OA | Bayer Pharma Aktiengesellschaft |
| 18912442 | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Non-Final OA | Jazz Pharmaceuticals Research UK Limited |
| 18554158 | CANCER TREATMENT USING PARP INHIBITORS AND PLK1 INHIBITORS | Non-Final OA | Cardiff Oncology, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy